drugset / Trial / NCT02038673
An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objectives of this study are to determine the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in participants with solid tumors.
Timeline
- Start
- 2013-11-05
- Primary completion
- 2017-07-19
- Completion
- 2017-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASP5878 | Small molecule | 0.5 mg | Oral |
| Subject | ASP5878 | Small molecule | 1 mg | Oral |
| Subject | ASP5878 | Small molecule | 2 mg | Oral |
| Subject | ASP5878 | Small molecule | 4 mg | Oral |
| Subject | ASP5878 | Small molecule | 6 mg | Oral |
| Subject | ASP5878 | Small molecule | 10 mg | Oral |
| Subject | ASP5878 | Small molecule | 16 mg | Oral |
| Subject | ASP5878 | Small molecule | 20 mg | Oral |